Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Portfolio Pulse from
Catalyst Pharmaceuticals has settled a patent litigation with Teva Pharmaceuticals regarding FIRDAPSE®. As part of the settlement, Teva will receive a license to market a generic version of FIRDAPSE starting in February 2035.
January 08, 2025 | 5:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Catalyst Pharmaceuticals has reached a settlement with Teva Pharmaceuticals over the FIRDAPSE® patent, allowing Teva to market a generic version starting in 2035.
The settlement resolves ongoing litigation, which removes legal uncertainty for Catalyst Pharmaceuticals. However, the impact on the stock price is neutral in the short term as the generic entry is set for 2035, far in the future.
CONFIDENCE 95
IMPORTANCE 70
RELEVANCE 90